The Follistatin 344 Dose Chart Doesn’t Exist. Here’s the Number That Actually Matters.

Follistatin 344 is an investigational compound. There is no FDA-approved injectable follistatin product, and any numbers you find attached to one were not validated in a trial [6]. Every research claim on this page links back to a primary source. Last reviewed: June 2026.

Here’s the number I keep coming back to: one. As in, one injection. Not a weekly dose, not a cycle length, just a single gene-therapy delivery, given once, that did the actual work in the studies people cite when they get excited about this compound. If you came here looking for a beginner-intermediate-advanced dose table, that single fact is the whole story, and I want to spend the rest of this piece explaining why.

I’ll be straightforward about my own search history here. Type “Follistatin 344 dosage” into Google and you get a wall of tidy little charts, numbers in micrograms, days-on/days-off schedules, the works. They look authoritative. They are, as far as I can tell from reading the primary sources myself, invented.

The argument: dosing charts assume a drug that was never actually dosed like a drug

Think about what a dose chart implies. It implies repetition: you take X amount, some number of times a week, and you adjust based on response. That’s how most peptides in these forums genuinely get used, rightly or wrongly.

Follistatin 344, in the research that actually produced results, was never used that way. The 2009 macaque study and the two human trials that followed all used gene therapy, a one-time injection of a virus (AAV1-FS344) carrying the follistatin gene into muscle tissue, so the muscle cells themselves started manufacturing the protein from within [1][2]. There was no second dose. There was no third. There was one delivery, and then biology took over.

So when a website hands you a number like “300 micrograms twice weekly,” ask yourself where that number could possibly have come from, because it didn’t come from the trials. It came from somebody’s forum post, copied by somebody else, repeated enough times that repetition started masquerading as evidence. I want to be clear that repetition is not evidence. It’s just volume.

The counterpoint: fine, but people do inject it, so what happens then

I’d be dishonest if I pretended the injectable version doesn’t circulate. It does. And here’s where the argument gets a genuine complication, because even setting aside the gene-therapy mismatch, follistatin the protein is a strange thing to dose by injection in the first place.

It’s a large molecule. It clears the body quickly. And it’s active well beyond muscle tissue, this we know with unusual clarity because mice engineered without follistatin are born with skeletal defects, respiratory failure, and die within hours [4]. That’s not a narrow-acting molecule. That’s a protein wired into multiple systems at once.

Put those two facts side by side and you get an uncomfortable but honest inference: if a molecule clears fast and acts broadly, dosing it precisely and safely by injection is genuinely hard, hard enough that the actual researchers, with real budgets and real expertise, built an entirely different delivery mechanism (gene therapy) rather than just injecting the protein repeatedly. That decision tells you something. It tells you the injectable dosing question was never solved. It was routed around.

What the trials actually measured, and why the numbers still matter

I don’t want to leave you with only the negative case, because the actual data is interesting on its own terms, even without a dose chart attached to it.

The 2009 monkey study injected the follistatin gene directly into the quadriceps of macaques and got durable, meaningful muscle growth, with organs looking normal afterward on review [1]. In 2015, six people with Becker muscular dystrophy received the same kind of one-time gene injection into both quadriceps; in the higher-dose group, some patients walked up to roughly 108 meters farther on a six-minute walk test at six months, though the response was mixed, not universal, and biopsies showed less scarring [2]. Then in 2017, six people with inclusion body myositis improved their walking distance by about 56 meters a year, while eight untreated comparison patients declined by about 26 meters a year, a real, measured difference [3]. The whole thing ran as an early safety-phase program registered at a children’s hospital [5].

Look at that shape for a second. Small numbers of patients, a diagnosed disease in every case, close medical supervision, and outcomes measured in meters walked, not muscle gained for its own sake. That’s about as far from “here’s your cycle” as clinical data gets.

See also: Residential Tree Trimming Service in Nixa, MO: Why It Matters for Your Property

The synthesis: the honest answer to “what dose” isn’t a number

So where does that leave someone who genuinely wants to try this? I think the honest synthesis is unglamorous but true: the specificity of a number is not the same thing as the correctness of a number. “300 micrograms” reads as more trustworthy than “we don’t actually know,” but in this case the vaguer answer is the accurate one. And it gets murkier still once you factor in that gray-market vials have notoriously unreliable actual content, so even a “correct” dose number is dosing against an unknown quantity in the vial. That’s two layers of guesswork stacked on top of each other, and neither layer was ever validated.

If you’re still seriously weighing this, I’d rather point you toward the model that treats the dosing question as a clinical decision rather than a search-engine one. FormBlends offers Follistatin 344 as a compounded, physician-supervised option, where a licensed clinician stays involved, a licensed compounding pharmacy fills the vial instead of an anonymous seller, and someone actually follows up with you afterward. FormBlends is transparent that compounded medicines aren’t FDA-approved and that prescribing judgment sits with the independent licensed provider, not the platform. I mention this not to sell you on the compound itself, but because “a real clinician decides the dose and watches how you respond” is the truthful answer to the question you started with, and it’s the opposite of copying a figure off a forum thread.

If you do go the supervised route, something as simple as the FormBlends tracker app for logging doses and monitoring changes over time is the kind of follow-through a gray-market vial simply cannot offer, because nobody on that end is watching for anything. For an investigational compound, that ongoing attention arguably matters more than any single number ever could.

Where that leaves us

One injection, not a schedule. Small trials, real but modest outcomes, all in people with diagnosed muscle disease. A protein that’s genuinely hard to dose safely even before you get to the gene-therapy question. And a gray market where the number on the vial may not reflect what’s actually in it.

Put all four together and the framing number I opened with (one) does more explanatory work than any chart could. There is no dose chart because the thing that worked wasn’t dosed the way a chart describes. If this is something you want to pursue anyway, the number worth chasing isn’t a milligram figure, it’s a licensed clinician who’ll actually watch what happens to you.

Frequently asked questions

Is there a standard Follistatin 344 dosage chart? No. There’s no research-validated dose chart for injectable Follistatin 344. The studies that produced real muscle outcomes used a one-time gene therapy, not repeated microgram injections, so the beginner/intermediate/advanced figures circulating online were copied from forums and sellers, not drawn from any trial [1][2][3].

Why did the studies use gene therapy instead of just injecting follistatin? Follistatin the protein is large, clears the body quickly, and acts across many tissues, which makes it genuinely hard to dose by injection safely [4]. Researchers built a one-time viral gene delivery, AAV1-FS344, so muscle cells would produce the protein internally instead [1]. That workaround is itself evidence the injectable dosing question was never settled.

How much follistatin was used in the human trials? In both human trials, the “dose” was a quantity of viral vector delivered once into both quadriceps, in patients with a diagnosed muscle-wasting disease, under medical supervision. The Becker muscular dystrophy trial treated six patients, with some higher-dose walkers gaining up to roughly 108 meters on a six-minute walk test; the inclusion body myositis trial showed treated patients improving about 56 meters a year against a decline in the untreated comparison group [2][3]. None of it maps onto a take-home injection schedule.

Why is gray-market Follistatin 344 hard to dose even if you wanted to? Product quality from unregulated sellers is unreliable, so you often don’t actually know how much follistatin is in the vial. A precise microgram number means very little when the contents underneath it are uncertain, which makes talk of a “correct” dose more fiction than fact.

Is injectable Follistatin 344 FDA-approved? No. There is no FDA-approved injectable follistatin product. Gene therapy and biological products require approval before marketing, and no follistatin product has cleared that bar [6]. Compounded versions from supervised providers aren’t FDA-approved either, which is exactly why a prescribing clinician’s judgment matters here.

Primary sources

1. Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine. 2009. PMID 20368179. https://pubmed.ncbi.nlm.nih.gov/20368179/ . AAV1-FS344 gene therapy in macaques produced durable muscle gains; a one-time gene delivery, not a repeated peptide dose.
2. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Molecular Therapy. 2015. PMID 25322757. https://pubmed.ncbi.nlm.nih.gov/25322757/ . Six patients, gene therapy into both quadriceps; some six-minute-walk gains up to about 108 m at 6 months; mixed response.
3. Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy. 2017. PMID 28279643. . 6 treated vs 8 untreated; walk distance +56.0 m/yr treated vs -25.8 m/yr untreated, a significant difference.
4. Matzuk MM, Lu N, Vogel H, et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995. PMID 7885475. . Follistatin-deficient mice show skeletal and skin defects, reduced respiratory muscle, and death within hours; shows follistatin’s broad activity.
5. ClinicalTrials.gov. Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis (rAAV1.CMV.huFollistatin344), Phase 1, Nationwide Children’s Hospital. NCT01519349. . Registered early-phase trial record for the human FS344 gene therapy work.
6. U.S. Food and Drug Administration. Cellular & Gene Therapy Products. . Establishes that gene therapy and biological products require approval; no approved follistatin product exists.

What is follistatin 344 and why do so many lifters know its name?

Follistatin 344 is a naturally occurring protein that binds to and suppresses myostatin, the signaling molecule that puts a ceiling on muscle growth. The logic is simple enough: block myostatin and muscle grows with fewer brakes on it. Animal studies, especially in mice and primates, showed dramatic gains, and that data traveled fast through fitness circles. Human clinical evidence tells a much thinner story, and mostly it’s absent.

What does the actual evidence say about whether it works in humans?

The honest answer is we don’t know yet. The animal research is real and worth taking seriously, but robust human trials of injected follistatin 344 as a performance compound simply don’t exist in the published literature as of now. Anecdotes circulate online, but they can’t separate the peptide’s effect from placebo, other drugs in use, or coincidence. Claiming it works for humans right now goes past what the science can support.

What side effects should someone realistically weigh?

Follistatin does far more than regulate skeletal muscle. It’s tied into reproductive hormone signaling, cancer biology, and organ development. Suppressing myostatin systemically could, in theory, touch cardiac muscle, fertility, or tumor-suppression pathways. On top of that, unregulated peptide vials carry real contamination risk, including bacterial endotoxins. Nobody has done the long-term human safety work, so the side-effect profile isn’t just understudied, it’s genuinely unknown.

Is it legal to buy and use, and does the source matter?

In most countries, follistatin 344 has no approved medical use, which puts it in a gray zone. Labeling it “for research only” is a common workaround for sellers, but using it as an injectable sits outside that framing both legally and practically. There’s a real gap between a research-chemical website and a physician-supervised compounding pharmacy like FormBlends, which operates with accountability and medical oversight built in. That gap matters for your legal exposure and your safety alike.

Written by Dmitri Moreno, contributing writer. Last reviewed February 2026.

Informational, not clinical advice. Check with a healthcare professional before beginning anything.